Related Experiment Video
Updated: Apr 21, 2026

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Updated guidelines for the management of axial disease in psoriatic arthritis
Peter Nash1, Ennio Lubrano2, Alberto Cauli2
1From the Department of Medicine, University of Queensland, Australia; Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise, Campobasso, Italy; Rheumatology Unit, Department of Medical Sciences, University of Cagliari, Cagliari, Italy; Rehabilitation Teaching and Research Unit, University of Otago, Wellington, New Zealand; Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Italy; and University of Toronto and Toronto Western Research Institute, Toronto, Ontario, Canada.P. Nash, MBBS (Hons), FRACP, Department of Medicine, University of Queensland; E. Lubrano, MD, PhD, Academic Rheumatology Unit, Department of Medicine and Health Sciences, University of Molise; A. Cauli, MD, PhD, Rheumatology Unit, Department of Medical Sciences, University of Cagliari; W.J. Taylor, MBChB, PhD, FRACP, Rehabilitation Teaching and Research Unit, University of Otago; I. Olivieri, MD, Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, Senior Scientist, Toronto Western Research Institute. drpnash@tpg.com.au.
Abstract:
Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial spondyloarthritis (SpA) defined by ASAS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologics and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Atherosclerosis III: Management
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Rheumatic Heart Disease IV: Nursing Management
Asthma-IV: Nursing Management
First, in...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

